罗沙司他治疗非透析慢性肾脏病患者贫血的成本-效用分析  

Cost-utility Analysis of Roxadustat for Anemia in Patients with Non-dialysis Chronic Kidney Disease

作　　者：段虹飞[1] 孙俊[1] 马培志[1] DUAN Hong-fei;SUN Jun;MA Pei-zhi(Department of Pharmacy,People's Hospital of Henan Province,Zhengzhou 450000,China)

机构地区：[1]河南省人民医院药学部,郑州450000

出　　处：《中国合理用药探索》2021年第9期15-19,共5页Chinese Journal of Rational Drug Use

摘　　要：目的:对罗沙司他治疗非透析慢性肾脏病(CKD)患者贫血进行药物经济学研究,为临床合理用药提供参考。方法:基于Markov模型,以国内医疗成本为成本数据,以国内外临床研究结果为疗效指标,利用Treeage软件模拟计算使用罗沙司他或安慰剂治疗非透析CKD患者贫血的质量调整生命年(QALY)及治疗成本,对比罗沙司他或安慰剂的成本效果,同时对成本、效用值进行单因素敏感度分析。结果:罗沙司他和安慰剂的总治疗成本分别为75710.93元和9972.88元,使用罗沙司他患者可获得的QALY为9.37,安慰剂组获得的QALY为8.67。增量成本效果比(ICER)分析显示,ICER为93911.5元/QALY,大于人均国民生产总值(GDP),小于3倍人均GDP。结论:单因素敏感度分析显示本研究结果稳定可靠。在我国目前经济形势下,罗沙司他治疗非透析CKD患者的贫血具有一定的成本-效用优势。Objective:Conduct an economic study on the treatment of anemia in patients with non-dialysis chronic kidney disease(CKD)with roxadustat,to provide a basis for clinical rational drug use.Methods:Based on Markov model,taking domestic medical cost as cost data and the results of clinical studies at home and abroad as the efficacy index,we used Treeage Software to calculate the quality-adjusted life year(QALY)and treatment costs for anemia in patients with non-dialysis CKD using roxadustat and placebo.Cost-effectiveness of roxadustat and placebo was compared;at the same time,the sensitivity analysis of cost and utility value was carried out.Results:The total treatment cost of roxadustat and placebo was 75710.93 yuan and 9972.88 yuan,respectively.The QALY available to patients using roxadustat was 9.37 and the QALY available to placebo was 8.67.The incremental cost-effectiveness ratio(ICER)analysis showed that the ICER was 93911.5 yuan/QALY,which was more than the per capita Gross Domestic Product(GDP),and less than three times of the per capita GDP.Conclusion:The single factor sensitivity analysis shows that the results are stable and reliable.In China’s current economic situation,for the treatment of anemia in patients with non-dialysis CKD,roxadustat has a certain cost-utility advantage.

关 键 词：罗沙司他 非透析慢性肾脏病 贫血 药物经济学 MARKOV模型 

分 类 号：R956[医药卫生—药学]